| Literature DB >> 22956807 |
James L Mohler1, Andrew J Armstrong, Robert R Bahnson, Barry Boston, J Erik Busby, Anthony Victor D'Amico, James A Eastham, Charles A Enke, Thomas Farrington, Celestia S Higano, Eric Mark Horwitz, Philip W Kantoff, Mark H Kawachi, Michael Kuettel, Richard J Lee, Gary R MacVicar, Arnold W Malcolm, David Miller, Elizabeth R Plimack, Julio M Pow-Sang, Mack Roach, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C Walsh, Maria Ho, Dorothy A Shead.
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation). Abiraterone acetate also received category 2B recommendations in the prechemotherapy setting for asymptomatic patients or symptomatic patients who are not candidates for docetaxel. The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with high-risk localized tumors or locally advanced disease.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22956807 DOI： 10.6004/jnccn.2012.0114
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908